[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"patents-list":3},{"list":4,"total":343,"page":344,"pageSize":345,"totalPages":346},[5,25,37,49,60,72,84,96,107,117,128,138,148,159,170,182,193,205,217,227,238,249,259,269,279,290,301,312,324,335],{"id":6,"patentNo":7,"title":8,"applicant":9,"inventors":10,"abstract":11,"ipc":12,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":17,"applicationNo":7,"publicationNo":13,"mainIpc":18,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":23,"tagNames":24},"gpi_00980","CN200910094354.6","乙型流感病毒Vero细胞高产适应株及其制备和应用","中国医学科学院医学生物学研究所","廖国阳;刘泽;孙明波;李卫东;高菁霞;马磊;周健;张新文;蔡玮;姜述德","本发明提供一种乙型流感病毒Vero细胞高产适应株及其制备和应用。所述乙型流感病毒Vero细胞高产适应株命名为：B\u002FYunnan\u002F2\u002F2005va(B)，该毒株保藏号为：CGMCCNo.2931。该毒株能在Vero细胞上连续传代培养，并且血凝效价可保持在1∶512以上。经检测，该毒株为乙型流感病毒，Yamagata谱系。该毒株含有乙型流感病毒的八个基因片段，且具有Vero细胞上持续高产的特性。一方面，将该毒株接种于Vero细胞，收集培养物上清，即得乙型流感病毒疫苗，实验证实，该疫苗具有良好的免疫原性和保护效力。另一方面，该毒株也可作为供体毒株，通过自然选择压力重配或反向遗传学重配，得到流行株在Vero细胞上的适应株，从而制备出流行株Vero细胞流感疫苗。","C12N7\u002F00;C12N7\u002F08;A61K39\u002F145;A61P31\u002F16;C12N15\u002F85;C12N7\u002F01;C12R1\u002F93",null,"2026-10-12T00:54:35.109Z",false,"发明专利","2010.01.06#公开;2010.03.03#实质审查的生效;2011.08.24#授权","C12N7\u002F00",true,"gpi5份","530000;云南省","粤港澳知识产权大数据综合服务平台(www.gpic.gd.cn)·广东省知识产权保护中心",[],[],{"id":26,"patentNo":27,"title":28,"applicant":29,"inventors":30,"abstract":31,"ipc":32,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":33,"applicationNo":27,"publicationNo":13,"mainIpc":34,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":35,"tagNames":36},"gpi_01013","CN200910094264.7","滇蛙抗氧化肽及其基因和应用","中国科学院昆明动物研究所","赖仞;杨海龙;王旭;刘秀红;武静;刘存宝","本发明涉及一种滇蛙抗氧化肽及其基因和应用，属于生物医学技术领域。滇蛙抗氧化肽是中国两栖类动物滇蛙基因编码的一种单链多肽，分子量为1653.88道尔顿，等电点8.22，滇蛙抗氧化肽全序列为：NH2－GIRPTYNRQCEIGF－COOH。编码的基因由316个核苷酸组成，其中编码成熟部分的为第130－171位核苷酸。人工合成的滇蛙抗氧化肽具有强烈的抗氧化活性，能作为制备皮肤抗氧化保护和体内自由基清除药物的应用，并且还具有序列简单、合成方便的优点。","C07K7\u002F08;C12N15\u002F12;A61K38\u002F10;A61P39\u002F06;A61P17\u002F18","2010.02.03#公开;2010.03.24#实质审查的生效;2011.07.20#授权","C07K7\u002F08",[],[],{"id":38,"patentNo":39,"title":40,"applicant":41,"inventors":42,"abstract":43,"ipc":44,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":45,"applicationNo":39,"publicationNo":13,"mainIpc":46,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":47,"tagNames":48},"gpi_01086","CN200910095051.6","乌药烷型二聚倍半萜类化合物,其制备方法及其在制药中的应用","中国科学院昆明植物研究所;昆明医学院","刘海洋;李玲;陈昌祥;孙玲;藤菲;黄年旭;冉新辉;倪伟;郝小江;高锁","本发明涉及从金粟兰属(Chloranthus)植物中分离得到的乌药烷型二聚倍半萜类(结构式I和II)化合物，它们的制备方法，以及在治疗2型糖尿病、肥胖症及其它引起的并发症的药物中的应用。式I和II中R1－R17为氢，或氧，或羟基，或酰基(乙酰基、当归酰基、羟基当归酰基、惕各酰基、千里光酰基、羟基千里光酰基、羧基千里光酰基、1，4－丁二酰基)，或双键、或烷基(甲基)，或R16和R17之间可以形成大环内酯，X为氧或氮。通过生物实验证明本发明的化合物具有较强的胰岛素增敏活性。","C07D493\u002F10;C07D493\u002F20;C07D307\u002F94;A61K31\u002F365;A61P3\u002F10;A61P3\u002F04;A23L1\u002F29","2010.03.17#公开;2010.04.28#实质审查的生效;2012.05.02#授权;2022.06.28#专利实施许可合同备案的生效、变更及注销","C07D493\u002F10",[],[],{"id":50,"patentNo":51,"title":52,"applicant":9,"inventors":53,"abstract":54,"ipc":55,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":56,"applicationNo":51,"publicationNo":13,"mainIpc":57,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":58,"tagNames":59},"gpi_01665","CN201010179190.X","轮状病毒P[2]G3株和P[8]G1株在KMB17细胞上适应培养方法和免疫原性","孙茂盛;李鸿钧;易山;马应霞;张光明;吴晋元","轮状病毒P[2]G3株和P[8]G1株在KMB17细胞上适应性培养和免疫原性，属于病毒培养方法。本发明将两株轮状病毒在KMB17细胞上连续10代适应培养，使细胞病变随病毒代次逐渐增快，感染性滴度递增并稳定在较高水平。病毒滴度分别达到7.75CCID50\u002Fml及7.33CCID50\u002Fml。病毒适应KMB17细胞且基因组稳定，用复制的病毒免疫小鼠其血清中和抗体效价分别为1∶16384及1∶8192。本发明适应性培养轮状病毒P[2]G3株株和P[8]G1株可在KMB17细胞中稳定复制，所产生病毒保持了亲本毒株的基本生物学特性，且有较好免疫原性。","C12N7\u002F08;C12Q1\u002F70;C12Q1\u002F68;G01N33\u002F569","2010.12.01#公开;2011.01.12#实质审查的生效;2011.09.28#授权","C12N7\u002F08",[],[],{"id":61,"patentNo":62,"title":63,"applicant":64,"inventors":65,"abstract":66,"ipc":67,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":68,"applicationNo":62,"publicationNo":13,"mainIpc":69,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":70,"tagNames":71},"gpi_01638","CN201010140771.2","分子标记检测N基因控制的烟草TMV抗性的方法","云南省烟草农业科学研究院","高玉龙;肖炳光;卢秀萍;陈学军;焦芳婵;李永平","本发明涉及一种检测烟草普通花叶病抗性基因(N gene)的分子标记方法，包括引物设计、基因组DNA提取、PCR扩增及电泳检测，根据烟草TMV抗性基因(N gene)核苷酸序列设计特异引物，通过PCR反应能够在含有TMV抗性基因(N gene)的烟草品种(系)中扩增得到一条1200bp左右的特征条带，从而达到检测烟草品种(系)是否具有对TMV抗性的目的。利用本发明的分子标记对84份烤烟材料进行检测，结果与品种(系)的TMV抗性相吻合。本发明操作简便、结果可靠、检测速度快、不受植株生长发育时期的影响，将本发明应用于烤烟TMV抗性品种的选育，可以大大提高选择效率。","C12Q1\u002F68;C12R1\u002F94","2010.11.24#公开;2011.01.05#实质审查的生效;2012.04.04#授权","C12Q1\u002F68",[],[],{"id":73,"patentNo":74,"title":75,"applicant":76,"inventors":77,"abstract":78,"ipc":79,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":80,"applicationNo":74,"publicationNo":13,"mainIpc":81,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":82,"tagNames":83},"gpi_01846","CN201010521880.9","治疗坐骨神经痛的中药及其制备方法与应用","中国科学院昆明植物研究所","程永现;吕青;陈小亮","本发明涉及一种治疗坐骨神经痛的中药复方及其制备方法。本发明的中药复方主要是由白术，白芷，制何首乌，延胡索，川芎，制川乌，木香，小茴香，川牛膝，木瓜组成，根据每味药有效成分的理化性质进行提取，按照常规方法制成口服固体或液体剂型。本发明具有温中散寒，健脾祛湿，活血行气、止痛的功效。临床试验证明本发明对坐骨神经痛有确切的疗效，且见效时间短，无毒副作用。","A61K36\u002F732;A61K36\u002F754;A61K36\u002F888;A61K36\u002F8984;A61K36\u002F889;A61K36\u002F896;A61P25\u002F02;A61P29\u002F00;A61K35\u002F32","2011.02.02#公开;2011.03.23#实质审查的生效;2011.12.21#授权;2022.06.28#专利实施许可合同备案的生效、变更及注销;2024.07.02#开放许可的声明及撤回","A61K36\u002F732",[],[],{"id":85,"patentNo":86,"title":87,"applicant":88,"inventors":89,"abstract":90,"ipc":91,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":92,"applicationNo":86,"publicationNo":13,"mainIpc":93,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":94,"tagNames":95},"gpi_01866","CN201010274265.2","对癌细胞有选择性的铂(Ⅱ)抗癌配合物","昆明贵金属研究所;中国科学院昆明植物研究所","刘伟平;李艳;谌喜珠;叶青松;李兴尧;苏佳;侯树谦;余尧;常桥稳","本发明涉及一种新型的铂(Ⅱ)抗癌配合物，以3-X-1，1-环丁烷二羧酸根作离去基团，以mixed-NH3\u002F环戊胺或mixed-NH3\u002F环己胺为载体，X是环丁烷上第三位碳上的极性取代基，分别为羟基OH，乙酰氧基OCOCH3和二氯乙酰氧基OCOCHCl2，同时该化合物可以含0，1，2个结晶水。本发明的化合物可以采用常规方法合成，它们不但具有高抗癌活性，而且对癌细胞有高的选择性，优于目前临床上广泛使用的抗癌药顺铂和卡铂。同时，这些化合物还具有水溶性好、稳定的优点，可以制成注射剂，用于临床治疗癌症。","C07F15\u002F00;A61K31\u002F282;A61P35\u002F00","2011.02.09#公开;2011.03.23#实质审查的生效;2012.07.25#授权","C07F15\u002F00",[],[],{"id":97,"patentNo":98,"title":99,"applicant":76,"inventors":100,"abstract":101,"ipc":102,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":103,"applicationNo":98,"publicationNo":13,"mainIpc":104,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":105,"tagNames":106},"gpi_01879","CN201010506212.9","以土大黄提取物为有效成份的抗焦虑药物及其制备方法和应用","程永现;梅任强;陈小亮;赵君","以土大黄提取物或有效部位为主要有效成份制备的药物，以中药材土大黄为主要有效成份制成片剂、颗粒剂、胶囊剂、口服液等口服给药剂型，可加入其它成份和辅料组成复方制剂，具有显著的抗焦虑效果，可用于焦虑症的保健和治疗。此外，还提供以土大黄提取物和食品添加剂组合成的保健食品，药物和食品的制备方法。","A61K36\u002F70;A23L1\u002F30;A61P25\u002F22","2011.02.16#公开;2011.03.30#实质审查的生效;2011.11.16#授权","A61K36\u002F70",[],[],{"id":108,"patentNo":109,"title":110,"applicant":9,"inventors":111,"abstract":112,"ipc":113,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":114,"applicationNo":109,"publicationNo":13,"mainIpc":113,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":115,"tagNames":116},"gpi_01880","CN201010513414.6","磷酸锌疫苗佐剂","胡云章;胡凝珠;王海漩","本发明涉及一种磷酸锌疫苗佐剂，尤其涉及磷酸锌作为疫苗佐剂的应用，以及磷酸锌疫苗佐剂在制备疫苗中的应用。所述磷酸锌作为疫苗佐剂与疫苗联合应用，能够有效增强疫苗的体液免疫应答，其免疫增强效果优于铝佐剂和氢氧化锌佐剂，并且经动物试验结果显示：磷酸锌作为疫苗佐剂其致敏性和安全性均优于铝佐剂和氢氧化锌佐剂。","A61K39\u002F39","2011.02.16#公开;2011.03.30#实质审查的生效;2012.09.26#授权",[],[],{"id":118,"patentNo":119,"title":120,"applicant":9,"inventors":121,"abstract":122,"ipc":123,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":124,"applicationNo":119,"publicationNo":13,"mainIpc":125,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":126,"tagNames":127},"gpi_01893","CN201010295467.5","病毒解裂剂及解裂病毒抗原抗体复合物并检测HCV抗原的方法","龙润乡;谢忠平;杨蓉;白惠珠;李华;董丽娟;蒋蕊鞠;崔萍芳","本发明提供一种病毒解裂剂及解裂病毒抗原抗体复合物并检测HCV抗原的方法，其特征在于每100ml裂解剂中含有：去垢剂0.1～1ml，蛋白变性剂0～20g，还原剂0.01～1ml，脂溶剂0.1～1ml，基础液余量。以对待检血样或抗血清与病毒抗原经中和反应后得到的抗原抗体复合物进行裂解处理成游离组分，或将病毒核心抗原得以充分暴露，并保留其抗原反应性，不仅使灵敏度较现有的HCV核心抗原检测法明显提高，而且由于抗原检测窗口期比抗HCV抗体窗口期平均缩短49天，在HCV-RNA出现后的1～2d内出现，可有效缩短血清转换前的窗口期，对于提高窗口期感染者的检出率、提高输血和血制品的安全性具有重要意义。本发明提供的病毒裂解剂适用于包括丙型肝炎病毒(HCV)、甲型肝炎病毒(HAV)在内的常见病毒抗原抗体复合物的解裂。","G01N33\u002F569;G01N21\u002F31;C07K16\u002F10;C07K16\u002F06;C07K1\u002F22","2011.02.16#公开;2011.03.30#实质审查的生效;2013.08.21#授权","G01N33\u002F569",[],[],{"id":129,"patentNo":130,"title":131,"applicant":9,"inventors":132,"abstract":133,"ipc":134,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":135,"applicationNo":130,"publicationNo":13,"mainIpc":113,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":136,"tagNames":137},"gpi_00010","CN200610048769.6","新型疫苗佐剂","胡云章;胡凝珠;瞿素","本发明涉及一种新型疫苗佐剂，即低分子量乙酰硫酸肝素在制备免疫疫苗的佐剂方面的应用。所述低分子量乙酰硫酸肝素与疫苗联合应用能够有效增强疫苗的体液免疫应答，增强效果与铝佐剂相似，并且所述新型疫苗佐剂能够显著增强疫苗的细胞免疫应答，适应于治疗性疫苗。","A61K39\u002F39;A61P31\u002F12;A61P1\u002F16","2007.04.11#公开;2007.06.06#实质审查的生效;2008.07.09#授权",[],[],{"id":139,"patentNo":140,"title":141,"applicant":9,"inventors":132,"abstract":142,"ipc":143,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":144,"applicationNo":140,"publicationNo":13,"mainIpc":145,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":146,"tagNames":147},"gpi_00056","CN200610048814.8","重组噬菌体流感疫苗","本发明涉及分子生物学、疫苗学领域，是一种噬菌体展示的广谱流感疫苗，并进一步涉及噬菌体展示的广谱流感疫苗的制备方法。由于流感病毒高度变异，现有的流感疫苗不能提供针对不同型别的流感病毒的保护。本发明将高度保守的A型流感病毒包膜蛋白M的胞外区M2e编码基因和B型流感病毒高度保守的包膜蛋白BM2的部分编码基因插入T7噬菌体，构建成普适性的重组噬菌体流感疫苗，进一步制备成重组噬菌体流感微球疫苗。本疫苗经预防接种后，能同时提供对A型流感病毒不同亚型和B型流感病毒攻击的保护作用。","A61K39\u002F295;A61K39\u002F145;C12N15\u002F44;C12N7\u002F01;A61P31\u002F16;A61P11\u002F00","2007.08.15#公开;2007.10.10#实质审查的生效;2010.08.25#授权","A61K39\u002F295",[],[],{"id":149,"patentNo":150,"title":151,"applicant":9,"inventors":152,"abstract":153,"ipc":154,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":155,"applicationNo":150,"publicationNo":13,"mainIpc":156,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":157,"tagNames":158},"gpi_00061","CN200710065708.5","一种轮状病毒灭活疫苗的制备方法","刘馨;孙茂盛","本发明公开了一种轮状病毒灭活疫苗的制备方法。该方法使轮状病毒株G1，G2，G3，G4适应至人二倍体细胞系，并在人二倍体细胞系上高效繁殖，将制得的轮状病毒作为轮状病毒灭活疫苗的生产毒株。其中，所述的人二倍体细胞系为KMB17。本发明选用人二倍体细胞系作为灭活轮状病毒疫苗生产的细胞基质，与现有的其它细胞基质相比，更安全。因此，利用建立的技术平台，可以采用轮状病毒的其它血清型作为研究对象，开发成为轮状病毒灭活疫苗。","A61K39\u002F15;A61P31\u002F14;C12N7\u002F00;C12N5\u002F08","2007.08.22#公开;2007.10.17#实质审查的生效;2010.12.29#授权","A61K39\u002F15",[],[],{"id":160,"patentNo":161,"title":162,"applicant":29,"inventors":163,"abstract":164,"ipc":165,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":166,"applicationNo":161,"publicationNo":13,"mainIpc":167,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":168,"tagNames":169},"gpi_00065","CN200710065665.0","一种新型环状小肽BA及其应用","赖仞;李建许;李东升","本发明涉及一种新型环状小肽BA及其应用，属于生物医学技术领域。本发明的环状小肽BA，分子量1259.56道尔顿，等电点4.44，具有一定的丝氨酸蛋白酶抑制剂活性，无酶活性。其全序列为：Cys Trp Thr Lys Ser Ile Pro ProLys Pro Cys(CWTKSIPPKPC)，第1位半胱氨酸和第11位的半胱氨酸形成分子内二硫键。该环状小肽BA作为药物设计模版及作为制备治疗肿瘤药物的应用。以环状小肽BA作为模版，在其氨基端和羰基端分别进行不同氨基酸的增加，得到具有抗菌活性或丝氨酸蛋白酶抑制剂活性的环状小肽BA1和环状小肽BA2，并作为制备治疗肿瘤、胃炎、胰腺炎药物的应用。本发明还具有序列简单、合成方便等优点。","C07K7\u002F06;C07K7\u002F08;A61K38\u002F08;A61K38\u002F10;A61K38\u002F16;A61P35\u002F00;A61P1\u002F04;A61P1\u002F18","2007.08.29#公开;2007.10.24#实质审查的生效;2009.08.05#授权","C07K7\u002F06",[],[],{"id":171,"patentNo":172,"title":173,"applicant":174,"inventors":175,"abstract":176,"ipc":177,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":178,"applicationNo":172,"publicationNo":13,"mainIpc":179,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":180,"tagNames":181},"gpi_00091","CN200710065886.8","治疗痛风的外用药物组合物","云南省药物研究所","朱兆云;王京昆;尚建华;刘波;徐榕雪;谢建平;钟关萍;杨坤芬;孙敏;崔涛;段丽萍;毛勇","本发明涉及一种治疗痛风的外用药物组合物，特别是涉及一种以植物中草药为原料制成的治疗痛风的外用药物组合物。本发明所述的治疗痛风的外用药物组合物是由以下重量配比的原料制成的外用剂型：丽江山慈菇10－30份、金叶子5－15份、披麻草5－15份、黄柏10－30份、白芨10－30份、大黄10－30份、薄荷脑0.5－1.5份。本外用药物组合物用于痛风疾病的治疗。","A61K36\u002F898;A61K9\u002F00;A61K9\u002F06;A61K9\u002F12;A61K9\u002F70;A61K47\u002F32;A61K47\u002F34;A61K47\u002F36;A61K47\u002F38;A61P19\u002F06;A61K31\u002F045","2007.10.31#公开;2007.12.26#实质审查的生效;2009.09.23#授权;2022.07.12#专利实施许可合同备案的生效、变更及注销","A61K36\u002F898",[],[],{"id":183,"patentNo":184,"title":185,"applicant":29,"inventors":186,"abstract":187,"ipc":188,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":189,"applicationNo":184,"publicationNo":13,"mainIpc":190,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":191,"tagNames":192},"gpi_00235","CN200810058075.X","姚虻唾液腺免疫调节肽及其基因和应用","赖仞;武静;徐学清;李东升;马冬莹","本发明涉及一种姚虻唾液腺免疫调节肽及其基因和应用，属于生物医学领域。该免疫调节肽是中国虻科昆虫唾液腺免疫调节肽基因编码的一种线状多肽，其全序列为：甘氨酸－甘氨酸－缬氨酸－丝氨酸－甘氨酸－缬氨酸－丝氨酸－天冬氨酸－苯丙氨酸－谷氨酸－脯氨酸－异亮氨酸－谷氨酸－缬氨酸－丝氨酸－甘氨酸－谷氨酸－天冬氨酸－酪氨酸－天冬酰胺－丝氨酸－天冬氨酸－谷氨酸－丙氨酸－天冬氨酸－谷氨酸－天冬氨酸－甘氨酸－赖氨酸－丙氨酸。免疫调节肽基因由362个核苷酸组成，其中编码成熟编码姚虻唾液腺免疫调节肽为第115－204位核苷酸。该姚虻唾液腺免疫调节肽作为抑制多种细胞因子的应用。本发明的免疫调节肽具有结构简单、人工合成方便、抗菌活性强等特点。","C07K14\u002F435;C12N15\u002F12;C12N15\u002F10;A61P37\u002F02","2008.07.16#公开;2008.09.10#实质审查的生效;2011.08.24#授权","C07K14\u002F435",[],[],{"id":194,"patentNo":195,"title":196,"applicant":197,"inventors":198,"abstract":199,"ipc":200,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":201,"applicationNo":195,"publicationNo":13,"mainIpc":202,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":203,"tagNames":204},"gpi_00274","CN200810058170.X","15－氧代绣线菊内酯，其药物组合物和其制备方法及其应用","中国科学院昆明植物研究所;中国科学院动物研究所","郝小江;陈全;刘海洋;赵丽霞;邸迎彤;金海京;何红平;乐雯;高锁;王晓慧;杜蕾","提供由结构式(1)所示的15－氧代绣线菊内酯(15－oxospiramilactone)化合物，其作为药物活性成分的抗肿瘤药物组合物，该化合物及其组合物可以克服因Bax缺失而引起的肿瘤细胞的抗药性以及克服Bcl－2高表达引起的肿瘤细胞对化疗药物的抗性，诱导Bcl－2高表达的细胞发生凋亡；诱导Bax和Bak双缺失的小鼠胚胎上皮细胞发生凋亡；抑制HCT116 Bax－\u002F－移植裸鼠肿瘤生长，显示15－氧代绣线菊内酯可以作为化疗药物，在杀伤对多种化疗药物有抗性的肿瘤细胞时，对动物体没有明显损害。","C07D311\u002F94;A61K31\u002F352;A61P35\u002F00","2008.08.13#公开;2008.10.08#实质审查的生效;2012.01.04#授权","C07D311\u002F94",[],[],{"id":206,"patentNo":207,"title":208,"applicant":209,"inventors":210,"abstract":211,"ipc":212,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":213,"applicationNo":207,"publicationNo":13,"mainIpc":214,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":215,"tagNames":216},"gpi_00303","CN200810058263.2","一种城市电网最大供电能力在线评估方法","昆明理工大学","束洪春;胡泽江;董俊;刘可真;孙士云;唐岚;刘志坚;孙向飞;杨毅;常勇;单节杉;刘永泰","本发明涉及一种城市电网最大供电能力在线评估方法，属电力系统调度高级应用技术领域。本发明利用数据库连接方式(ADO与ODBC)，读取EMS中相关的网络拓扑及节点信息，借助邻接矩阵对城市电网进行拓扑分析，建立一种计算城市电网最大供电能力的模型，该模型是一种基于直流潮流的线性规划模型，它以网络所能供应的最大负荷为目标函数，以网络的功率平衡、各支路的额定容量、节点的功率约束为约束条件。在程序中利用改进单纯型法对线性规划问题进行求解，并对求解结果进行误差分析。该模型对于轻负荷网络具有计算速度快，计算结果误差不大的特点，适合应用于需要反复进行优化调整的电网中。应用该程序进行大量的计算，计算结果证明该方法的有效性和适用性。","H02J3\u002F00;G06F17\u002F00;G06Q50\u002F00","2008.08.27#公开;2008.10.22#实质审查的生效;2013.06.12#授权","H02J3\u002F00",[],[],{"id":218,"patentNo":219,"title":220,"applicant":9,"inventors":221,"abstract":222,"ipc":223,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":224,"applicationNo":219,"publicationNo":13,"mainIpc":34,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":225,"tagNames":226},"gpi_00359","CN200810058472.7","能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途","代解杰;罕园园;孙晓梅;高家红;唐东红;匡德宣","一种能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途，具体为来自结核杆菌的具有疫苗开发前景的抗原表位的分子模拟肽及其编码DNA，本发明提供了结核杆菌研究中一个重要基因Ag85B中所包含的T淋巴细胞抗原表位，并提供了推断或筛选这些抗原表位的方法，有益于进一步开发出新型的多联多聚表位结核疫苗，更有效的预防和控制结核病的发生和发展；为今后利用上述抗原表位进行合成肽疫苗、表位疫苗及核酸疫苗的开发奠定了基础；提供了一种能激发机体抗结核杆菌的保护性免疫反应的抗原表位的分子模拟肽，所述肽含有选自以下的氨基酸序列：FVRSSNLKFQDAYNA(SEQ ID NO：1)。","C07K7\u002F08;C07K1\u002F00;C12N15\u002F09;G01N33\u002F68;A61K39\u002F00;A61P31\u002F06","2008.10.22#公开;2009.07.22#实质审查的生效;2011.06.29#授权",[],[],{"id":228,"patentNo":229,"title":230,"applicant":76,"inventors":231,"abstract":232,"ipc":233,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":234,"applicationNo":229,"publicationNo":13,"mainIpc":235,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":236,"tagNames":237},"gpi_00396","CN200810058703.4","毛萼乙素结晶、其制备方法及含有其的药物组合物","孙汉董;朱兆云;吕扬;普建新;杜冠华;肖伟烈;常颖;强桂芬;王京昆","本发明提供一种具有如下结构式的毛萼乙素化合物的新晶型，毛萼乙素的英文名称为eriocalyxin B。本发明还提供毛萼乙素新晶型的制备方法，以及含有该毛萼乙素新晶型为活性成分的药物组合物；本发明的毛萼乙素新晶型以及含有该新晶型的药物组合物具有优异的生物利用度，能够在预防或治疗癌症中发挥更好的临床作用。","C07D493\u002F08;A61K31\u002F35;A61P35\u002F00","2008.12.10#公开;2009.02.04#实质审查的生效;2010.11.24#授权;2024.07.12#专利权人的姓名或者名称、国籍和地址的变更;2024.10.22#开放许可的声明及撤回","C07D493\u002F08",[],[],{"id":239,"patentNo":240,"title":241,"applicant":9,"inventors":242,"abstract":243,"ipc":244,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":245,"applicationNo":240,"publicationNo":13,"mainIpc":246,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":247,"tagNames":248},"gpi_00420","CN200810058812.6","冻干甲型肝炎减毒活疫苗及其制备方法","胡云章;胡凝珠;任万军;王海漩","本发明涉及一种冻干甲型肝炎减毒活疫苗及其制备方法，所述疫苗由下列体积比的原料组成：甲型肝炎减毒活疫苗∶冻干保护剂＝1∶0.5～1.5，其中冻干保护剂即海藻糖与甘氨酸的混合水溶液的组成为：海藻糖2～10克\u002F100毫升，甘氨酸3.2～16克\u002F100毫升，溶剂为水，其中溶质甘氨酸与海藻糖的质量比即甘氨酸∶海藻糖≥1.6。将疫苗与冻干保护剂混合合，经过冻干工艺制得。本发明提供的冻干甲型肝炎减毒活疫苗与现有的液体疫苗相比，冻干后其感染性滴度无显著变化，但其热稳定性显著提高，并且经动物实验证实具有良好的安全性与免疫原性。冻干甲型肝炎减毒活疫苗的有效期可延长至18个月，而液体剂型只为6个月，具有重大经济效益和应用价值。","A61K39\u002F29;A61K47\u002F26;A61P1\u002F16;A61P31\u002F14","2009.01.07#公开;2009.02.25#实质审查的生效;2012.03.28#授权","A61K39\u002F29",[],[],{"id":250,"patentNo":251,"title":252,"applicant":9,"inventors":253,"abstract":254,"ipc":255,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":256,"applicationNo":251,"publicationNo":13,"mainIpc":18,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":257,"tagNames":258},"gpi_00532","CN200810233583.7","一种EV－71病毒毒种、人用灭活疫苗及其制备方法","李琦涵;董承红;刘龙丁;谢忠平;王丽春;马绍辉;崔萍芳;梁燕;刘云霞;唐松清","本发明公开了一种EV－71病毒毒种、人用灭活疫苗及其制备方法。其毒种的分类命名为肠道病毒71型，保藏编号为CGMCC№.2701，所制成的人用EV－71灭活疫苗的组成为：EV－71活纯化抗原100μg\u002Fml，氢氧化铝0.8～1mg\u002Fml，硫柳汞0.05～0.1mg\u002Fml。试验表明该疫苗制品具有良好的免疫原性和安全性。","C12N7\u002F00;C12N7\u002F06;A61K39\u002F125;A61P31\u002F14","2009.04.08#公开;2009.06.03#实质审查的生效;2010.12.22#授权",[],[],{"id":260,"patentNo":261,"title":262,"applicant":9,"inventors":263,"abstract":264,"ipc":265,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":266,"applicationNo":261,"publicationNo":13,"mainIpc":57,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":267,"tagNames":268},"gpi_00834","CN200910094223.8","甲型流感病毒Vero细胞适应株及其应用","廖国阳;范东瀛;孙明波;李卫东;周健;张英伟;姜述德","本发明公开了一种甲型流感病毒Vero细胞适应株及其应用，所述甲型流感病毒Vero细胞适应株命名为A\u002FYunnan\u002F1\u002F2005Va(H3N2)，该毒株的保藏号为CCTCC NO：V200514。该毒株含有H3亚型血凝素基因、N2亚型神经氨酸酶基因和具有在Vero细胞上高产性状流感病毒的6个内部基因。将该毒株在Vero细胞上连续传代培养，血凝滴度可保持在1024以上。该毒株可作为供体株与流行株遗传重配，或采用反向遗传学技术，将其6个内部基因与流行株2个表面蛋白基因进行基因重配，获得流行株的Vero细胞适应株，最终使用这一适应株制备Vero细胞流感疫苗或Vero细胞大流行流感疫苗。","C12N7\u002F08;C12N15\u002F85;C12N7\u002F01;A61K39\u002F145;A61P31\u002F16;C12R1\u002F93","2009.10.21#公开;2009.12.16#实质审查的生效;2011.01.12#授权",[],[],{"id":270,"patentNo":271,"title":272,"applicant":9,"inventors":273,"abstract":274,"ipc":275,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":276,"applicationNo":271,"publicationNo":13,"mainIpc":125,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":277,"tagNames":278},"gpi_01042","CN200910094972.0","EV71型病毒抗原的检测方法","李琦涵;谢忠平;龙润乡;董承红;杨蓉;白惠珠;李华;崔萍芳;刘龙丁","本发明提供一种EV71型病毒抗原检测方法，它将待检EV71型病毒抗原、抗原阳性对照和抗原阴性对照分别加入酶标板的孔中，再在酶标板的各孔依次加入稀释度为1∶500～3000的生物素标记EV71型抗体，稀释度为1∶2000～10000的辣根过氧化物酶标记的链霉亲和素，TMB显色液A和B，最后在酶标板的各孔中加入终止液后，置于酶标仪上，在450nm波长下，用空白孔调零后检测吸光度A值，即得检测结果。本检测可从一般细胞培养病变法的3－5天缩短为数小时，在较短时间内确诊患者感染的病原体，且在基层医院和防控中心就可完成检测，能及时对症治疗和对疫情进行预防控制，是一种特异性好、灵敏度高、方便快捷的EV71病毒抗原检测方法。","G01N33\u002F569;G01N33\u002F543;G01N33\u002F52;G01N1\u002F34;C07K14\u002F085;C07K1\u002F14","2010.02.24#公开;2010.04.28#实质审查的生效;2014.04.23#授权",[],[],{"id":280,"patentNo":281,"title":282,"applicant":283,"inventors":284,"abstract":285,"ipc":286,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":287,"applicationNo":281,"publicationNo":13,"mainIpc":113,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":288,"tagNames":289},"gpi_01659","CN201010230599.X","一种锁阳免疫佐剂及含有该佐剂的流感疫苗","中国医学科学院医学生物学研究所;中国科学院昆明植物研究所","李映波;程永现;毕湖冰;吕青;陈芹芹","本发明涉及一种锁阳免疫佐剂及含有该佐剂的流感疫苗，其中锁阳免疫佐剂由下列质量比的组分组成：锁阳提取物0.001～100％，载体0～99.999％。所述含有锁阳免疫佐剂的流感疫苗的组成是：锁阳免疫佐剂与流感疫苗血凝素的质量比为50～150000。本发明提供的锁阳佐剂具有显著的免疫佐剂效果，用于各种人、兽疫苗中，能起到有效的疾病防治作用。锁阳提取物作为流感疫苗的免疫佐剂，与传统氢氧化铝佐剂比较，其使用安全性高、副作用小，能更好地提高流感疫苗免疫原性，在制备流感疫苗过程中，其方法简便，经济环保，质量容易控制，大大降低了流感疫苗抗原用量，能够满足流行性流感暴发时的免疫需求。","A61K39\u002F39;A61K39\u002F145;A61K36\u002F185;A61P31\u002F16;A61P37\u002F04;A61K135\u002F00","2010.12.01#公开;2011.01.12#实质审查的生效;2013.12.04#授权",[],[],{"id":291,"patentNo":292,"title":293,"applicant":209,"inventors":294,"abstract":295,"ipc":296,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":297,"applicationNo":292,"publicationNo":13,"mainIpc":298,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":299,"tagNames":300},"gpi_01437","CN201010168418.5","用于验证多相搅拌混合均匀状态及程度的方法","王华;徐建新;范国峰;朱道飞;王仕博;孙辉","本发明公开一种用于验证多相搅拌混合均匀状态及程度的方法。主要应用于化学工程实验中判断流体混合效果及理论上指导实验。具体是：(1)利用电子断层成像技术或高速摄像机来获得多相搅拌混合实时图样；(2)用编写好的程序计算所获得的实时图样的第0维贝蒂数或分形维数；(3)用(2)中的方法每隔一定时间获得相关数据，从而得到相应时间序列；(4)利用0-1test方法判断(3)中得到的时间序列是否混沌从而判断是否混合均匀；(5)然后用(4)中所得数据和1的接近程度来判断混合均匀的程度。本发明应用在对所有流体混合效果的检测，该方法简单方便，且具有很高的实用价值，对化工实验中判断混合效果及理论上指导搅拌反应器的设计，提供了一种可靠实用的验证方法。","G01N21\u002F958;G01N23\u002F04;G06F7\u002F00","2010.08.25#公开;2010.10.13#实质审查的生效;2013.05.15#授权","G01N21\u002F958",[],[],{"id":302,"patentNo":303,"title":304,"applicant":64,"inventors":305,"abstract":306,"ipc":307,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":308,"applicationNo":303,"publicationNo":13,"mainIpc":309,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":310,"tagNames":311},"gpi_01463","CN201010110901.8","一种利用大肠杆菌表达烟草富含甘氨酸RNA结合蛋白的方法","李文正;陈禹保;刘勇;陈学军;卢秀萍;唐启慧","本发明公开了一种利用大肠杆菌表达烟草富含甘氨酸RNA结合蛋白(GRP)的方法，包括表达菌株筛选、培养基优化、蛋白提取缓冲液配制，其特征在于：具体包括下列工序：A、提取烟草总RNA，逆转录成cDNA，PCR扩增出GRP蛋白基因；B、构建重组表达质粒pGEX4T-1-GRP；C、转化大肠杆菌表达菌株、小量诱导筛选高效表达菌株、大量诱导表达；D、蛋白提取和E、蛋白活性鉴定。本发明通过筛选大肠杆菌高效表达菌株，优化培养基，克隆基因构建出GRP基因重组表达质粒pGEX4T-1-GRP，再用阳性质粒对菌种为rosetta的大肠杆菌菌株进行转化，并采用优化的专用培养基LinA培养、缓冲液TKM，筛选出了高效表达菌株，从而提高了烟草中富含甘氨酸RNA结合蛋白的表达效率。本发明具有成本低、操作简单、生产周期短、适于大规模生产、蛋白表达率高、活性强，易于纯化、不易降解的优点。","C12N15\u002F70;C12N15\u002F29;C12N1\u002F21;C07K14\u002F415","2010.09.08#公开;2010.10.27#实质审查的生效;2012.07.18#授权","C12N15\u002F70",[],[],{"id":313,"patentNo":314,"title":315,"applicant":316,"inventors":317,"abstract":318,"ipc":319,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":320,"applicationNo":314,"publicationNo":13,"mainIpc":321,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":322,"tagNames":323},"gpi_01470","CN201010171168.0","一种治疗泌尿系感染和结石病的药物","西双版纳傣族自治州民族医药研究所","段立纲;林艳芳;赵应红;岩罕单;廖瑞玲;玉腊波;谭志刚;潘玉秀;刀红英;曾君;王孝蓉;肖丽香;刀会仙;陈亚梅;刘志强;邓群;刘扬扬","一种治疗泌尿系感染和结石病的药物，由下述重量份的药材制成：盾翅藤1-5，野芦谷根1-3，圆锥南蛇藤1-3，肾茶1-3，甘草1-2；本发明制备的药品用于治疗急、慢性肾炎，肾盂炎，尿路感染，肾、输尿管、膀胱结石等病症；应用现代技术研制成不同的剂型应用于临床，收到显著的疗效，经临床疗效观察和急毒试验，主要药效学研究证明，未发现毒副反应，疗效安全可靠，疗效显著，具有很好的开发应用前景和市场竞争力。","A61K36\u002F53;A61P13\u002F00;A61P31\u002F00;A61P13\u002F04;A61P13\u002F12;A61P13\u002F02;A61K35\u002F37","2010.09.15#公开;2010.11.03#实质审查的生效;2012.07.04#授权","A61K36\u002F53",[],[],{"id":325,"patentNo":326,"title":327,"applicant":316,"inventors":328,"abstract":329,"ipc":330,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":331,"applicationNo":326,"publicationNo":13,"mainIpc":332,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":333,"tagNames":334},"gpi_01471","CN201010171251.8","一种治疗疔疮的外搽酊剂","林艳芳;段立纲;赵应红;岩罕单;廖瑞玲;玉腊波;谭志刚;潘玉秀;刀红英;曾君;王孝蓉;肖丽香;刀会仙;陈亚梅;刘志强;邓群;刘扬扬","一种治疗疔疮的外搽酊剂，由下述重量份的原料药制成：余甘子树皮1-4，云南石梓树皮1-4，台乌1-4，十大功劳1-3，雄黄1-3；本发明提供的药物具有清热解毒，收敛止痒的功能；该药物经临床疗效观察和急毒试验，未发现毒副反应，疗效安全可靠，疗效显著，具有很好的开发应用前景和市场竞争力。","A61K36\u002F85;A61K9\u002F08;A61P17\u002F00;A61P31\u002F22;A61P17\u002F04;A61K33\u002F36","2010.09.15#公开;2010.11.03#实质审查的生效;2011.12.07#授权","A61K36\u002F85",[],[],{"id":336,"patentNo":337,"title":338,"applicant":316,"inventors":328,"abstract":339,"ipc":340,"publishDate":13,"sourceUrl":13,"achievementId":13,"createdAt":14,"isOpenLicense":15,"licenseTerm":13,"licenseScope":13,"licenseFeeText":13,"licenseFeeNum":13,"patentType":16,"legalStatus":331,"applicationNo":337,"publicationNo":13,"mainIpc":179,"agency":13,"agent":13,"publishOrg":13,"provinceCode":13,"filingDate":13,"isRevitalized":19,"maintainYears":13,"isFunded":13,"implStatus1":13,"implStatus2":13,"willingness1":13,"willingness2":13,"feeWan":13,"intendedCity":13,"intendedCompany":13,"intendedPrice":13,"techMaturity":13,"starRating":13,"gbIndustryClass":13,"strategicClass":13,"productAdv":13,"prospect":13,"comboName":13,"batch":20,"province":21,"sourceText":22,"tags":341,"tagNames":342},"gpi_01474","CN201010171271.5","一种治疗肝病的药物","一种治疗肝病的药物，由以下重量份的药物组成：柴胡1，百样解4，十大功劳1.25，枸杞2.25，五味子1.75，丹参1.25，山楂3.5，槟榔2.5，甘草0.5；有健脾舒肝，活血止痛，保肝利胆之功能。用于治疗肝胆功能失调，胆汁、毒物排泄失常而发生的肝胆疾病，如甲、乙肝病、脂肪肝、酒精肝、肝癌、胆囊炎、胆石症等。","A61K36\u002F898;A61K36\u002F9066;A61P1\u002F16;A61P31\u002F14;A61P31\u002F20;A61P35\u002F00",[],[],54,1,30,2]